A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

Trial Profile

A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Denosumab (Primary)
  • Indications Bone resorption; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Dec 2016 Planned End Date changed from 1 Nov 2018 to 1 Sep 2018.
    • 18 Nov 2016 This trial has been completed in Czech Republic, according to European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top